Citi Downgrades Biogen (BIIB) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Opicinumab Phase 2 Miss No Surprise; Leerink Affirms Biogen (BIIB) at 'Market Perform'
June 7, 2016 11:54 AM EDTLeerink affirms Biogen (Nasdaq: BIIB) with a Market Perform rating and $319 price target after the company announced that its Phase 2 SYNERGY study of opicinumab... More
Biogen (BIIB) Opicinumamb's Miss Focuses Investors on Aducanumab - BMO
June 7, 2016 9:46 AM EDTBMO analyst, Nathaniel Smith, expects Biogen (NASDAQ: BIIB) shares to trade down on top-line results from opicinumambs (anti-LINGO) Phase 2 trial in multiple sclerosis, which showed that it missed on both the primary and secondary endpoints. The analyst believes comments regarding a complex... More
Biogen (BIIB) Phase 2 Study of Opicinumab Missed Primary Endpoint
June 7, 2016 7:33 AM EDTBiogen (NASDAQ: BIIB) reported top-line results from the Phase 2 SYNERGY study evaluating opicinumab (anti-LINGO-1), an investigational, fully human monoclonal antibody being developed as a potential neuroreparative therapy in people with relapsing forms of multiple sclerosis (RMS). In the study, opicinumab missed the primary endpoint, a multicomponent measure evaluating improvement of physical function, cognitive function, and... More
